May 19, 2021 8:00am EDT MAIA Biotechnology, Inc. Raises $8.0 Million Financing to Advance Pipeline of Targeted Immuno-Oncology Studies
Feb 02, 2021 8:00am EST MAIA Biotechnology, Inc. Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating THIO in Sequential Administration with Libtayo® (cemiplimab) in Advanced Non-Small Cell Lung Cancer
